The growing global incidence of breast cancer has led to an increased demand for molecular diagnostics tests that aid in diagnosing breast cancer.
Patients with this genetic variant are more likely to experience adverse drug reactions or failure of treatment.
General Electric announced Friday that its healthcare unit will acquire molecular diagnostics company Clarient in a deal worth approximately $580 million.
Operating for over 50 years, Safeguard Scientifics is a holding company that provides capital, as well as strategic, operational and management resources for technology and life sciences companies.
Father’s Day is just around the corner, but many dads won’t be around to celebrate. Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death among men in the U.S.
Before a physician can prescribe pills or recommend a therapy, the patient must be diagnosed.
Clarient, a provider of comprehensive anatomic pathology and molecular testing services, will acquire Applied Genomics in an all-stock merger worth up to $17.6 million.